First Interim Efficacy and Safety Analysis of an International Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with Chemotherapy with or without Alemtuzumab and Consolidated by High Dose Therapy

dxxxAmore, F, Leppa, S, da Silva, MC, Relander, T, Brown, PD, Weidmann, E, Lauritzsen, GF, Pezzutto, A, Van Hoof, A, van Gelder, M, Doorduijn, JK, Wu, KL, Kluin-Nelemans, JC, Lugtenburg, PJ, Jankovska, M, Merup, M, Fagerli, UM, Walewski, J, Hagberg, H, Mariz, JM, Hansen, PB, Nosslinger, T, Janssens, A, Brandefors, L, Demuynck, H, Schaafsma, MR, Christiansen, I, Salek, D, Jyrkkio, S, Prochazka, V, Zijlstra, J, Bohmer, L, Greil, R, Stevens, W, Fijnheer, R, Kooy, MV, Grube, M, Hopfinger, G, Van den Neste, E, Jantunen, E, Trumper, L, Wulf, G, Altmann, B, Ziepert, M, Loeffler, M, Toldbod, H BLOOD. 2012, 120(21):

Lenalidomide/Rituximab Maintenance After Induction With Fludarabine/Rituximab In Combination With Escalating Doses Of Lenalidomide In Previously Untreated Chronic Lymphocytic Leukemia (CLL): The Revlirit CLL5 AGMT Phase I/II Study, Final Results

Vornamen sind ausgeschrieben-Г¤ndern? Alexander Egle, Michael Steurer, Franz Josef Gassner, Roland Geisberger, Thomas Melchardt, Lisa Pleyer, Lukas Weiss, Michael A. Fridrik, Josef Thaler, Alois Lang, Richard Greil, Blood (ASH Annual Meeting Abstracts). 2013. #4164:

RITUXIMAB PLUS SUBCUTANEOUS CLADRIBINE IN PATIENTS WITH EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA OF THE MUCOSA ASSOCIATED TISSUE (MALT-LYMPHOMA): A PHASE II STUDY BY THE AGMT (ARBEITSGEMEINSCHAFT MEDIKAMENTOSE TUMORTHERAPIE)

Troch, M, Kiesewetter, B, Willenbacher, W, Willenbacher, E, Zebisch, A, Linkesch, W, Fridrik, MA, Mullauer, L, Greil, R, Raderer, M ANN ONCOL. 2012, 23: 352-352.

IMPACT OF NUMBER OF PREVIOUS TREATMENT LINES AND PRE-TREATMENT WITH BORTEZOMIB OR LENALIDOMIDE ON EFFICACY OF BORTEZOMIB-BENDAMUSTINE-DEXAMETHASONE (BBD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)

Ludwig, H, Kasparu, H, Leitgeb, C, Greil, R, Rauch, E, Linkesch, W, Zojer, N, Pour, L, Fillitz, M, Adam, Z ANN ONCOL. 2012, 23: 348-349.

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: results of a randomised phase III intergroup study initiated by the AIO and AGMT (ML18147)

Greil, R, Arnold, D, Hegewisch-Becker, S, Freier, W, Steffens, CC, Bertram, M, Schlichting, C, Andel, J, Taylor, M, Makrutzki, M, Kubicka, S ONKOLOGIE. 2012, 35: 254-254.

Influence of the American ODAC statement upon Austrian prescription practice of bevacizumab in metastatic breast cancer

Preusser, M, Fulop, G, Berghoff, AS, Heinzl, H, Steger, GG, Greil, R, Zielinski, CC, Bartsch, R ONKOLOGIE. 2012, 35: 66-66. und erschienen unter: Oncologist. 2012,17(7):e13-7. doi: 10.1634/theoncologist.2012-0115. Epub 2012 Jun 27.

BIOMARKER (BM) RESULTS FROM THE PHASE III AVEREL TRIAL OF 1ST-LINE BEVACIZUMAB (BV), TRASTUZUMAB (H) plus DOCETAXEL (T) FOR HER2-POSITIVE LOCALLY RECURRENT/METASTATIC BREAST CANCER (LR/MBC)

Gianni, L, Chan, A, Mansutti, M, Pivot, X, Greil, R, Provencher, L, Prot, S, Moore, N, Scherer, SJ, Pallaud, C ANN ONCOL. 2012, 23: 531-532.

Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study).

Arnold, D, Andre, T, Bennouna, J, Sastre, J, Osterlund, PJ, Greil, R, Van Cutsem, E, Von Moos, R, Reyes-Rivera, I, Bendahmane, B, Kubicka, S J CLIN ONCOL. 2012, 30(18):

The role of biomarkers in the choice of therapy in triple negative breast cancer

Mlineritsch B Ressler S Greil R memo – Magazine of European Medical Oncology. 2012, 5: 101-104.

A 55-year-old woman with locally advanced rectal cancer and a resectable synchronous hepatic metastasis: a case report.

Hohla, F, Mayer, P, Hutter, J, MeiГџnitzer, T, Greil, R, memo – Magazine of European Medical Oncology. 2012, 5 (4): 273-276.